Protagonist Therapeutics PTGX Cash Flow Statement (2015-2026)

NASDAQ PTGX
$145.65 -3.15 (-2.12%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Protagonist Therapeutics Quarterly Cash Flow Statement

Periods 45 quarters
Latest Jun 2026

Protagonist Therapeutics reported cash from operations of $219.05M and free cash flow of $218.44M for the quarter ended Jun 2026, up 861.1% year over year. This cash flow statement covers 45 quarters of results from Jun 2015 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-33.80M-37.15M-20.94M-40.96M-31.15M-34.27M-33.73M-38.46M-34.10M43.91M207.34M-30.59M-33.21M77.22M-11.65M-34.80M-39.34M-16.84M3.78M162.81M
Share-based Compensation
4.78M5.02M6.81M6.83M6.44M5.51M8.16M8.34M6.76M6.60M9.35M2.57M12.05M9.09M13.80M2.92M5.66M10.70M23.37M9.74M
Deferred Taxes
Gains from Investment Securities
Cash from Operations
-28.47M-26.94M-37.67M-13.63M-25.20M-31.64M-34.35M-26.24M-26.61M16.96M-27.43M268.62M-27.86M-29.18M125.36M-28.78M-1.94M-36.98M-48.94M219.05M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
0.49M0.58M0.58M0.58M0.58M0.58M1.25M0.96M1.01M1.35M1.61M1.66M2.84M2.76M2.29M1.91M1.68M1.34M1.02M1.05M
Amortization of Deferred Charges
0.49M
Depreciation & Amortization (CF)Depreciation & Amortization
0.25M0.26M0.27M0.26M0.25M0.24M0.24M0.25M0.24M0.24M0.23M0.12M0.24M0.30M0.36M0.38M0.41M0.40M
Change in Working Capital
Change in Account Payables
-10.95M0.45M5.56M-6.38M3.94M-1.08M0.38M0.55M-3.20M-0.60M2.83M-0.20M-0.35M-1.43M1.24M0.38M2.42M-0.31M3.00M-4.90M
Change in Accured Expenses
13.01M4.70M-5.11M3.56M-6.57M-4.59M-8.38M2.72M5.40M-5.34M-2.87M-1.36M5.29M3.23M-11.82M3.44M7.54M5.41M-10.79M4.19M
Change in Taxes
3.33M-0.68M-1.60M1.64M-0.80M-1.89M
Other Working Capital Changes
1.21M0.59M-1.28M1.53M-0.67M-3.34M-0.79M-1.42M0.63M-0.17M0.92M2.01M1.16M-0.32M0.95M1.10M-0.05M0.36M1.92M-4.22M
Investing Activities
Capital Expenditures
0.27M0.20M0.27M0.29M0.16M0.07M0.01M0.17M0.40M0.02M0.24M0.03M0.77M0.31M0.55M0.81M0.09M0.14M0.21M0.62M
Change in Acquisitions & Divestments
48.00M58.75M51.63M81.31M89.59M84.60M37.90M32.00M45.80M36.70M71.98M86.86M58.73M105.99M113.18M122.78M102.65M153.23M156.69M132.41M
Cash from Investing Activities
-44.71M27.87M-4.48M34.73M57.27M3.94M9.83M25.76M-13.56M-61.29M6.07M-88.12M-208.71M-8.72M-94.40M54.81M-58.55M48.81M90.89M-2.43M
Financing Activities
Other financing activities
1.38M2.34M2.56M0.66M0.68M0.55M2.26M0.97M1.02M0.52M7.80M2.57M12.05M4.03M11.92M2.92M5.66M2.84M23.37M9.74M
Debt Issuance and Repayment
Long-Term Debt Issuances
14.55M24.30M
Change in Capital Stock
Net Shares Issued and Repurchased
1.12M2.20M2.52M2.07M1.11M
Net Equity Issued and Repurchased
-0.17M0.05M24.30M0.07M-0.08M0.01M
Misc.
Cash from Financing Activities
1.38M2.17M16.93M0.68M0.68M0.55M26.46M108.17M35.31M0.53M7.20M2.57M12.05M4.03M11.44M2.92M5.66M2.84M23.37M9.74M
Exchange Rate Effect
-0.07M0.02M0.03M-0.02M-0.17M0.07M
Change in Cash
-71.87M3.12M-25.19M21.76M32.58M-27.07M1.94M107.70M-4.86M-43.80M-14.16M183.07M-224.52M-33.87M42.40M28.95M-54.83M14.68M65.32M226.37M
Free Cash Flow
-28.73M-27.14M-37.94M-13.93M-25.36M-31.70M-34.36M-26.41M-27.02M16.94M-27.67M268.59M-28.63M-29.49M124.82M-29.59M-2.02M-37.12M-49.16M218.44M
Net Cash Flow
-71.80M3.10M-25.22M21.78M32.75M-27.15M1.94M107.70M-4.86M-43.80M-14.16M183.07M-224.52M-33.87M42.40M28.95M-54.83M14.68M65.32M226.37M